A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Bristol-Myers Squibb
AbbVie
M.D. Anderson Cancer Center
ImmunoGen, Inc.
Canadian Cancer Trials Group
Mayo Clinic
GOG Foundation
University of California, Irvine
Chong Kun Dang Pharmaceutical
University Health Network, Toronto
AGO Study Group
University Health Network, Toronto
Vejle Hospital
City of Hope Medical Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GOG Foundation
GOG Foundation
Fox Chase Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NYU Langone Health
Montefiore Medical Center
NYU Langone Health
Georgetown University
Fred Hutchinson Cancer Center